-
The FDA has approved the first antineoplastic that acts by the inhibiting the formation of new blood vessels in tumors.
-
Migraine and Subclinical Brain Lesions; Memantine Treatment in Alzheimer Disease; PPG in Type 2 DM
-
Optimizing outcomes in patients with acute coronary syndrome requires matching patients with strategies that will produce the best results in specific clinical subgroups. Identifying those patients with ST elevation myocardial infarction (STEMI) who represent ideal candidates for fibrinolysis, and who are likely to have outcomes that are at least as favorable as they would have with percutaneous interventions, has become an area of intense focus among cardiologists and emergency physicians. Significant improvements in patient outcomes will be made when patients are managed according to their institutional capabilities, with the understanding that prompt thrombolysis in the setting of STEMI is fundamental to optimal patient care. This article, the second in a two-part series, provides a practical, evidence-based approach to comprehensive management of this patient population.
-
In patients with ALI/ARDS from pulmonary and extrapulmonary causes, receiving mechanical ventilation with low tidal volumes and high PEEP, short-term effects of recruitment maneuvers as conducted in this study are variable.
-
Steroids Not Linked to Risk of Fractures; ADT Puts Men at Risk for Osteoporosis; Study Shows Valsartan May Improve Sexual Function in Postmenopausal Women; New Direct-to-Consumer Pharma Advertising Rules Considered; FDA Actions
-
-
Drs. Stuart Connolly and Stefan Hohnloser presented results from the Defibrillator In Acute Myocardial Infarction Trial (DINAMIT). Prior studies had shown that patients with recent myocardial infarction and left ventricular dysfunction are at high risk for death in the period after myocardial infarction.
-
A 12-month program of regular exercise in selected patients with chronic stable angina and significant CAD resulted in a higher event-free survival and exercise capacity at lower costs than PCI.
-
-
High-dose atorvastatin protects patients with acute coronary syndrome from death and major cardiovascular events better than usual dose pravastatin.